Interaction of Hydroxychloroquine with Pharmacokinetically Important Drug Transporters
(1) Background: Hydroxychloroquine is used to treat malaria and autoimmune diseases, and its potential use against COVID-19 is currently under investigation. Thus far, information on interactions of hydroxychloroquine with drug transporters mediating drug-drug interactions is limited. We assessed th...
Main Authors: | Johanna Weiss, Gzona Bajraktari-Sylejmani, Walter E. Haefeli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/10/919 |
Similar Items
-
Extracellular Vesicles as Surrogates for Drug Metabolism and Clearance: Promise vs. Reality
by: Anna Gagliardi, et al.
Published: (2023-08-01) -
The aglycone diosmetin has the higher perpetrator drug-drug interaction potential compared to the parent flavone diosmin
by: Gzona Bajraktari, et al.
Published: (2020-04-01) -
Implications of the use of hydroxychloroquine on cardioactive drugs
by: Soumitra Ghosh, et al.
Published: (2021-01-01) -
2‐Deoxyglucose and hydroxychloroquine HPLC‐MS–MS analytical methods and pharmacokinetic interactions after oral co‐administration in male rats
by: Dongxiao Sun, et al.
Published: (2024-02-01) -
Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
by: Johanna Weiss, et al.
Published: (2016-02-01)